Inversago Pharma to Participate at the 2023 SVB Securities Global Biopharma Conference
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that François Ravenelle, Ph.D., Chief Executive Officer, and Glenn Vraniak, MBA, Chief Financial Officer, will host investor meetings during the Private Company Exhibition at the 2023 SVB Securities Global Biopharma Conference being held January 31 through February 2, 2023.
For additional information or to request a meeting with management, please contact conference representatives.
About Inversago Pharma
Inversago Pharma is a privately owned, clinical stage, Canadian biotech company, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting CB1 inverse agonists. Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as diabetic kidney disease (DKD), including diabetic nephropathy (DN), type 1 and type 2 diabetes (T1D / T2D), non-alcoholic steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications like progressive fibrosis-interstitial lung disease (PF-ILD), including idiopathic pulmonary fibrosis (IPF) and other conditions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Glenn S. Vraniak
Chief Financial Officer
Inversago Pharma Inc.
Media and Investors
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westfield Completes Acquisition of Lloyd’s of London Syndicate 12003.2.2023 00:18:00 EET | Press release
Westfield today announces the completion of its acquisition of Lloyd’s of London Syndicate 1200 from Argo Group International Holdings Ltd. (NYSE: ARGO). This strategic acquisition establishes Westfield as a global franchise, accelerates Westfield Specialty’sSM growth after a strong first 18 months in the U.S. market, and puts the overall Westfield Specialty portfolio in excess of $1 billion in premium. “This acquisition demonstrates Westfield’s commitment to the international specialty market,” says Westfield President, CEO and Board Chair Ed Largent. “The Lloyd’s of London market offers long-term growth opportunities and we’re excited to offer brokers, agents, and clients greater access to Westfield’s expertise and product offerings.” Westfield brings deep expertise and experience to the international specialty market. Westfield Specialty President Jack Kuhn has a wealth of experience leading global, multi-billion-dollar businesses. Together with Graham Evans, Westfield Specialty Exe
Mobile Commerce Platform Fintiv Partners with Geoswift to Enable Cross-border Digital Remittance in Asia2.2.2023 23:16:00 EET | Press release
Fintiv, a leading mobile commerce platform that brings together payments, loyalty programs, and mobile marketing in one place, has partnered with Geoswift, a payment technology company with significant expertise in Asian cross-border payments, to enable digital remittance payments into Asia through Fintiv’s versatile mobile wallets. The partnership will provide Fintiv’s customers the unique capability of making person-to-person or business-to-business payments into China, India, and many other Asian countries, directly from wallet accounts. With Geoswift’s superior geographical reach through its “GeoRemit” product line, Fintiv’s payment platform can now connect to an extensive number of domestic banks or mobile wallets in Asian countries and territories. For example, payments can be delivered instantly to either the UnionPay debit/credit cards or Alipay wallets of beneficiaries in China. “We are proud to announce a partnership with Geoswift as part of our global digital currency networ
SPIE Announces the Best Products in the Photonics Industry at its 15th Annual Prism Awards2.2.2023 21:22:00 EET | Press release
Yesterday, SPIE, the international society for optics and photonics, recognized the top-rated new optics and photonics products with the industry-focused Prism Awards. The gala evening, held during SPIE Photonics West, also marked the Prism Awards’ 15th anniversary with a champagne toast, a timeline gallery of past winners, and a video showcasing a decade and a half of Prism highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230202005690/en/ The 2023 SPIE Prism Awards: The evening's winners and presenters celebrate their successes and 15 years of photonics innovations. (Photo: Business Wire) Each year, the SPIE Prism Awards reflect the rapidly growing trajectory, exciting latest developments, and rich technical innovations across photonics and photonics-enabled industries. This year, the annual ceremony honored a range of established and emerging companies applying innovative and creative solutions to critical proble
European Authorities Approve Lyophilized S/D Treated Plasma OctaplasLG® for Pre-Hospital Transfusion2.2.2023 18:28:00 EET | Press release
Octapharma AG today announced that European medical authorities have approved the lyophilised presentation of the well-established octaplasLG® - pharmaceutically-licensed S/D treated plasma for transfusion. The line extension, which will be marketed in Europe as a powder and solvent for solution for infusion, offers new and potentially life-saving treatment options in pre-hospital and emergency settings. “The European authorization of octaplasLG® powder continues Octapharma's ongoing commitment to help prevent uncontrolled haemorrhage associated with trauma, which accounts for 30%-50% of all deaths in the first 24 hours"1-5, says Dr. Oliver Hegener, Vice President IBU Critical Care. Trauma results in 4.4 million deaths worldwide annually6, with uncontrolled bleeding being the major cause of potentially preventable death. Trauma-induced coagulopathy (TIC) is an early abnormal response characterised by hypocoagulation, in addition to acute blood loss, shock, hypothermia and metabolic aci
LTIMindtree Partners with Criteo to Drive IT Operational Efficiency2.2.2023 17:00:00 EET | Press release
LTIMindtree, a global technology consulting and digital solutions company, today announced a multi-year engagement that enables Criteo, the commerce media company, to enhance its business agility, IT service quality, and scalability. As part of the engagement, LTIMindtree provides end-to-end IT services to support Criteo’s global operations across all functions. This includes supporting Criteo’s Microsoft Azure Cloud environment, developing a unified data platform, and providing end-user services for its service desk, field, device engineering and Enterprise Service Management. “Enabling Criteo with modern IT systems and capabilities remains a key priority in this fast-moving business environment,” said Beatrice Mabille, VP Internal IT, Criteo. “We look forward to our continued strategic partnership with LTIMindtree.” “We are excited to be a part of Criteo’s business journey as its first-ever strategic IT outsourcing partner,” said Sudhir Chaturvedi, President and Executive Board Membe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom